Journal article
COMPASS for Vascular Surgeons
Abstract
PURPOSE OF REVIEW: To suggest a practical approach for the application of data from the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial in patients with peripheral artery disease (PAD).
RECENT FINDINGS: The COMPASS trial showed that low-dose rivaroxaban 2.5 mg twice daily plus daily aspirin was superior to aspirin alone in reducing major adverse cardiovascular and cerebrovascular events, and major adverse …
Authors
Hussain MA; Wheatcroft M; Nault P; Lindsay TF; Bhatt DL; Anand SS; Verma S; Al-Omran M
Journal
Current Opinion in Cardiology, Vol. 34, No. 2, pp. 178–184
Publisher
Wolters Kluwer
Publication Date
3 2019
DOI
10.1097/hco.0000000000000597
ISSN
0268-4705